Connect your AI

BridgeBio Pharma BBIO License — Receivables Long Term Contracts Or Programs

Discontinued — last reported Q2 '22

Similar metrics at other companies

PSXLoans and long-term receivables

$303M+74.1%

SCILong-term receivables, net

$1.57B-0.6%

ALLYLong-term receivables, net

$375M-22.2%

COPLong-term receivables, net

$110M-2.7%

EIXLong-term receivables, net

$36M-57.6%

SCILong Term — Financing Receivable, before Allowance for Credit Loss, Noncurrent

$9.94M-0.1%

Other financials

Income statement

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesLongTermContractsOrPrograms.

The official record: BridgeBio Pharma’s 10-Q, filed August 4, 2022, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's license — receivables long term contracts or programs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BridgeBio Pharma's license — receivables long term contracts or programs?: BridgeBio Pharma (BBIO) reported license — receivables long term contracts or programs of $600K in Q2 2022.
What does license — receivables long term contracts or programs mean?: This metric captures the portion of receivables from licensing and collaboration agreements that are expected to be collected beyond one year from the balance sheet date. It represents the long-term credit exposure to partners resulting from multi-year milestone payments or deferred consideration. Monitoring this helps assess the long-term collectability and credit risk associated with major licensing deals.